Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7α-hydroxylase in chronic renal failure

Nephrology Dialysis Transplantation

Volumn 12, Issue 7, 1997, Pages 1381-1386

  Liang, K ^a   Vaziri, N D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bile metabolism; Cholesterol 7 hydroxylase; HMG CoA reductase; Hypercholesterolaemia; LDL receptor; Nephrotic syndrome

Indexed keywords

CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CHOLESTEROL METABOLISM; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTAKE; RAT; RECEPTOR GENE;

ANIMALS; CHOLESTEROL 7-ALPHA-HYDROXYLASE; GENE EXPRESSION; HYDROXYMETHYLGLUTARYL COA REDUCTASES; KIDNEY FAILURE, CHRONIC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LDL; RNA, MESSENGER;

EID: 0030877777     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.7.1381     Document Type: Article

References (30)

1. Lindner AL, Charra B, Sherrard DJ, Scribner FJ. Accelerated atherosclerosis in prolonged maintenance hemodialysis. J N Engl Med 1974; 290: 697-701
2. Lazarus JM, Lowrie EG, Hampers CL, Merril JP. Cardiovascular disease in uremic patients on hemodialysis. Kidney Int 1975; 7 [Suppl 2]: S167-S175
3. Chan MK, Varghese Z, Moorehead JF. Lipid abnormalities in uremia, dialysis and transplantation. Kidney Int 1981; 19: 625-637
4. Kasiske BL, O'Donnel MP, Cowardin W, Keane WF. Lipids and the kidney. Hypertension 1990; 15: 443-450
5. Attman PO, Samuelson O, Alaupovic P. Lipoprotein metabolism in renal failure. Am J Kidney Dis 1993; 21: 573-592
6. Heuck CC, Liersch M, Ritz E, Stegmeier K, Wirth A, Mehls O. Hyperlipoproteinemia in experimental chronic renal insufficiency in the rat. Kidney Int 1978; 14: 142-150
7. Keilani T, Schluterer WA, Levin ML, Battle DC. Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin converting enzyme inhibitor. Ann Intern Med 1993; 118: 246-254
8. Heuck CC, Ritz E. Hyperlipoproteinemia in renal insufficiency. Nephron 1980; 25: 1-7
9. Attman PO, Gustafson A. Lipid and carbohydrate metabolism in uremia. Eur J Clin Invest 1979; 9: 185-291
10. Ibels LS, Reardon MF, Nestel PI. Plasma post-heparin lipolytic activity and triglyceride clearance in uremic and hemodialysis patients and renal allograft recipients. J Lab Clin Med 1976; 87: 648-658
11. Mordasini R, Frey F, Flurry W, Klose G, Greten H. Selective deficiency of hepatic triglyceride lipase in uremic patients. N Engl J Med 1977; 297: 1362-1366
12. Chan MK, Ramdial L, Varghese Z, Persaud JW, Bailload RA, Moorhead JF. Plasma lecithin-cholesterol acyltransferase activity in uremic patients. Clin Chem Ada 1982; 119: 65-72
13. Vaziri ND, Liang K. Down regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int 1996; 50: 1928-1935
14. Vaziri ND, Liang K. Down regulation of VLDL receptor in chronic experimental renal failure. Kidney Int 1997; 51: 913-919
15. Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG. Abnormalities in hepatic lipase in chronic renal failure: Role of excess parathyroid hormone. J Clin Invest 1996; 97: 2167-2173
16. Pollock CA, Wyndham R, Collect PV et al. Effects of erythropoietin therapy on the lipid profile in end-stage renal failure. Kidney Int 1994; 45: 897-902
17. Russell DW, Setchell KDR. Bile acid biosynthesis. Biochemistry 1992; 31: 4737-4748
18. Cooper AD. Hepatic lipoprotein and cholesterol metabolism. In: Boyer ZA, ed, Hepatology. WB Saunders, Philadelphia, 1989; 105-137
19. Pandak WM, Vlahcevic ZR, Heuman DM, Kreig RJ, Hanna JD, Chan JC. Post-transcriptional regulation of 3-hydroxy3-methylglutaryl coenzyme A reductase and cholesterol 7 alpha-hydroxylase in rats with subtotal nephrectomy. Kidney Int 1994; 46: 358-364
20. Vaziri ND, Zhou XJ, Naqvi F et al. Role of nitric-oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol (Endocrinol Metab) 1996; 23: E113-E123
21. Vaziri ND, Liang KH. Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 1995; 48: 1979-1985
22. Ness GC, Sample CE, Smith M, Pendleton LC, Eichler DC. Characteristics of rat liver microsomal 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Biochem J 1986; 233: 167-172
23. Simonet WS, Ness GC. Transcriptional and post-transcriptional regulation of rat hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase by thyroid hormone. J Biol Chem 1989; 264: 569-573
24. Shefer S, Nguyen LB, Salen G et al. Differing effects of cholesterol and taurocholate on steady state hepatic HMG-CoA reductase and cholesterol 7α-hydroxylase activities and mRNA levels in the rat. J Lipid Res 1992; 33: 493-501
25. Chiang JY, Miller WF, Lin GM. Regulation of cholesterol 7α-hydroxylase in the liver. Purification of cholesterol 7α-hydroxylase and the immunochemical evidence for induction of cholesterol 7α-hydroxylase by cholestyramine and circadian rhythm. J Biol Chem 1990; 265: 3889-3897
26. Liang KH, Oveisi F, Vaziri ND. Gene expression of hepatic cholesterol 7α-hydroxylase in the course of puromycin-induced nephrosis. Kidney Int 1996; 49: 855-860
27. Vaziri ND, Liang KH. Down regulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 1996; 50: 887-893
28. Horkko S, Huttunen K, Korhonen T, Kesaniemi YA. Decreased clearance of low-density lipoprotein in patients with chronic renal failure. Kidney Int 1994; 45: 561-570
29. Shapiro RJ. Catabolism of low-density lipoprotein is altered in experimental renal failure. Metabolism 1993; 42: 162-269
30. Nestel PJ, Fidge NH, Tan MH. Increased lipoprotein-remnant formation in chronic renal failure. N Eng J Med 1982; 307: 329-333